{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:04:09Z","timestamp":1778202249144,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To explore early features that can predict colchicine resistance in familial Mediterranean fever (FMF) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>It included FMF cases who fulfilled the Yalcinkaya\u2013Ozen criterion and were on colchicine for at least 6\u2009months. Data were collected from medical files and interpreted with respect to clinical parameters, incluing the auto-inflammatory diseases activity index (AIDAI) and FMF severity score. FMF50 score assessed the treatment response. Laboratory findings and genetic analysis of Mediterranean fever (MEFV) mutations were evaluated according to the standard technique. Patients were classified into two groups according to their response to colchicine. Both groups were compared, and significant variables were entered into a logistic regression model to detect independent predictors. The diagnostic accuracy of these predictors was assessed using the receiver operating characteristic curve.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In all, 120 FMF children were included. After the exclusion of 16 non-compliant patients (13.3%), colchicine responders were 66 (63.4%) (group I) and colchicine-resistant cases (group II) were 38 (36.5%). The fever duration after colchicine, number of attacks before\/after colchicine, skin rash\/erysipelas-like erythema, myalgia\/protracted febrile myalgia, AIDAI before\/after treatment, FMF severity score, and the maximum colchicine dose were higher in group II. Furthermore, high C-reactive protein and neutropenia were frequent in group II. However, different MEFV mutations, including M694V were similar between the two groups. Eight variables were detected in the regression analysis model, and independent predictors were utilized to generate a scoring model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study constructed a prediction model for colchicine nonresponse based on clinical and laboratory profiles. This model will be valuable for the treatment decisions of FMF children.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac068","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T10:16:24Z","timestamp":1657016184000},"page":"830-835","source":"Crossref","is-referenced-by-count":6,"title":["Early predictors of colchicine resistance in familial Mediterranean fever"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1220-7215","authenticated-orcid":false,"given":"Doaa","family":"Mosad Mosa","sequence":"first","affiliation":[{"name":"Rheumatology & Rehabilitation, Mansoura University Hospitals , Mansoura, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doaa","family":"Shokry","sequence":"additional","affiliation":[{"name":"Community & Public Health, Mansoura University Faculty of Medicine , Mansoura, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina B","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Mansoura University , Mansoura, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sobh","sequence":"additional","affiliation":[{"name":"Department of paediatrics, Mansoura University Faculty of Medicine , Mansoura, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2023070502120486000_R1","first-page":"318","article-title":"Familial Mediterranean fever: clinical, molecular and management advancements","volume":"65","author":"Lidar","year":"2007","journal-title":"Net J Med"},{"key":"2023070502120486000_R2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/annrheumdis-2012-202774","article-title":"Increased NLRP3-dependent interleukin 1beta secretion in patients with familial Mediterranean fever: correlation with MEFV genotype","volume":"73","author":"Omenetti","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2023070502120486000_R5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/14397595.2014.908810","article-title":"Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever","volume":"26","author":"Hamanoue","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2023070502120486000_R6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.autrev.2012.07.025","article-title":"Incomplete response to colchicine in M694V homozygote FMF patients","volume":"12","author":"Lidar","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2023070502120486000_R7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/rheumatology\/ken509","article-title":"A new set of criteria for the diagnosis of familial Mediterranean fever in childhood","volume":"48","author":"Yalc\u0131nkaya","year":"2009","journal-title":"Rheumatology"},{"key":"2023070502120486000_R8","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","article-title":"Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes","volume":"73","author":"Piram","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2015-208671","article-title":"Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF)","volume":"75","author":"Demirkaya","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/annrheumdis-2013-204719","article-title":"FMF50: a score for assessing outcome in familial Mediterranean fever","volume":"73","author":"Ozen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506129908993281","article-title":"MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever","volume":"6","author":"Livneh","year":"1999","journal-title":"Amyloid"},{"key":"2023070502120486000_R12","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0049-0172(96)80012-6","article-title":"The changing face of familial Mediterranean fever","volume":"26","author":"Livneh","year":"1996","journal-title":"Semin Arthritis Rheum"},{"key":"2023070502120486000_R13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/keu138","article-title":"Can colchicine response be predicted in familial Mediterranean fever patients?","volume":"53","author":"\u00d6z\u00e7akar","year":"2014","journal-title":"Rheumatology"},{"key":"2023070502120486000_R14","first-page":"1","article-title":"The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey","volume":"15","author":"Sahin","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023070502120486000_R15","doi-asserted-by":"crossref","DOI":"10.1186\/1824-7288-38-66","article-title":"The expanded clinical profile and the efficacy of colchicine therapy in Egyptian children suffering from familial Mediterranean fever: a descriptive study","volume":"38","author":"Talaat","year":"2012","journal-title":"Ital J Pediatr"},{"key":"2023070502120486000_R16","first-page":"87","article-title":"Familial Mediterranean fever in small children in Turkey","volume":"29","author":"Yalcinkaya","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2023070502120486000_R17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/annrheumdis-2012-202774","article-title":"Increased NLRP3-dependent interleukin 1b secretion in patients with familial Mediterranean fever: correlation with MEFV genotype","volume":"73","author":"Omenetti","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023070502120486000_R18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/S0049-0172(03)00137-9","article-title":"Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization","volume":"33","author":"Lidar","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"2023070502120486000_R19","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0609-1","article-title":"A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever","volume":"12","author":"Corsia","year":"2017","journal-title":"Orphanet J Rare Dis"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac068\/45047902\/roac068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/830\/50797259\/roac068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/830\/50797259\/roac068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:04:17Z","timestamp":1688526257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/4\/830\/6630108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac068","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,7,5]]}}}